EHNA
 | This article may be too technical for most readers to understand. (March 2021) |
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C14H23N5O |
| Molar mass | 277.372 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
EHNA (erythro-9-(2-hydroxy-3-nonly)adenine) is a potent adenosine deaminase inhibitor,[1] which also acts as a phosphodiesterase inhibitor that selectively inhibits phosphodiesterase type 2 (PDE2).[2][3]
References
[edit]- ^ "Sigma Aldrich". Retrieved 16 January 2013.
- ^ Podzuweit T, Nennstiel P, Müller A (September 1995). "Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3-nonyl) adenine". Cellular Signalling. 7 (7): 733–8. doi:10.1016/0898-6568(95)00042-N. PMID 8519602.
- ^ Méry PF, Pavoine C, Pecker F, Fischmeister R (July 1995). "Erythro-9-(2-hydroxy-3-nonyl)adenine inhibits cyclic GMP-stimulated phosphodiesterase in isolated cardiac myocytes". Molecular Pharmacology. 48 (1): 121–30. PMID 7623766.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |